ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Summary

A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2 (the MiR-AGE study).

Timeline

Start

2020-07-01

Primary completion

2021-03-05

Completion

2021-04-16

Outcome

Missed primary endpoint

Stopped: “Interim analysis concludes that the study is futile”

release “halting the miR-AGE phase 2b/3 clinical trial in high-risk Covid-19 patients after the independent Data Safety and Monitoring Board (DSMB) recommendation for lack of efficacy.” abivax.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obefazimod	Small molecule	50 mg	Oral

Indications